Oncologic Drugs Advisory Committee; Amendment of Notice

---
identifier: "/us/fr/2012-15393"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Oncologic Drugs Advisory Committee; Amendment of Notice"
title_number: 0
title_name: "Federal Register"
section_number: "2012-15393"
section_name: "Oncologic Drugs Advisory Committee; Amendment of Notice"
positive_law: false
currency: "2012-06-25"
last_updated: "2012-06-25"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2012-15393"
document_type: "notice"
publication_date: "2012-06-25"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "77 FR 37911"
fr_volume: 77
docket_ids:
  - "Docket No. FDA-2012-N-0001"
fr_action: "Notice."
---


#  Oncologic Drugs Advisory Committee; Amendment of Notice

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Oncologic Drugs Advisory Committee. This meeting was announced in the *Federal Register* of May 31, 2012 (77 FR 32125-32126). The amendment is being made to reflect a change in the *Date and Time,* and *Procedure* portions of the document. The *Date and Time* of the meeting will change to July 24, 2012, from 8 a.m. to 6 p.m. The *Procedure* portion of the document has changed to reflect an updated public participation time of 10:30 a.m. to 11 a.m., and 4:30 p.m. to 5 p.m. There are no other changes.

**FOR FURTHER INFORMATION CONTACT:**

Caleb Briggs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, *[email protected],* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting.

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of May 31, 2012, FDA announced that a meeting of the Oncologic Drugs Advisory Committee would be held on July 24, 2012. On page 32125, in the third column, the *Date and Time* portion of the document is changed to read as follows:

*Date and Time:* The meeting will be held on July 24, 2012 from 8 a.m. to 6 p.m.

On page 32126, in the first column, the third sentence in the *Procedure* portion of the document is changed to read as follows:

*Procedure:* Oral presentations from the public will be scheduled between approximately 10:30 a.m. to 11 a.m., and 4:30 p.m. to 5 p.m.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: June 20, 2012.

Jill Hartzler Warner,

Acting Associate Commissioner for Special Medical Programs.